Unlike most vaccines, which are manufactured using chicken eggs, UMN Pharma has a technology licensed from a U.S. bioventure for making the vaccine in cultured insect cells. Using this method, the company can produce its H5N1 vaccine in just eight weeks.
For the Phase II trials, it will work with two medical institutions to inoculate a total of 90 healthy subjects with one of three different dosages of UMN-0501. Each subject will be given two shots spaced three weeks apart. Data will be collected on the side effects, safety and the extent to which the vaccine provided immunity against the virus.
UMN Pharma will have the data analyzed by a U.S. research institute and expects to obtain the results by next February. At that time, it will plan its strategy for Phase III trials.
(Nikkei) rw

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index